Spearhead Capital Advisors LLC Grows Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)


Share on StockTwits

Spearhead Capital Advisors LLC raised its stake in Becton, Dickinson and Company (NYSE:BDX) by 25.6% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 30,500 shares of the medical instruments supplier’s stock after buying an additional 6,219 shares during the period. Spearhead Capital Advisors LLC’s holdings in Becton, Dickinson and were worth $7,416,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also bought and sold shares of the company. Flagship Private Wealth LLC bought a new stake in shares of Becton, Dickinson and in the 4th quarter valued at about $25,000. Kempen Capital Management N.V. bought a new position in shares of Becton, Dickinson and during the 4th quarter worth approximately $29,000. Sage Private Wealth Group LLC bought a new position in shares of Becton, Dickinson and during the 4th quarter worth approximately $37,000. Fort Pitt Capital Group LLC bought a new position in shares of Becton, Dickinson and during the 4th quarter worth approximately $38,000. Finally, Mcmillion Capital Management Inc. bought a new position in shares of Becton, Dickinson and during the 4th quarter worth approximately $40,000. Institutional investors and hedge funds own 83.22% of the company’s stock.

NYSE BDX traded down $2.52 during trading on Tuesday, hitting $250.60. The company’s stock had a trading volume of 7,083 shares, compared to its average volume of 1,312,288. Becton, Dickinson and Company has a 52 week low of $219.50 and a 52 week high of $284.97. The firm has a market cap of $72.81 billion, a P/E ratio of 92.72, a price-to-earnings-growth ratio of 2.34 and a beta of 0.79. The firm has a 50 day moving average price of $247.90 and a 200 day moving average price of $246.48. The company has a quick ratio of 1.07, a current ratio of 1.54 and a debt-to-equity ratio of 0.72.

Becton, Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Wednesday, February 3rd. The medical instruments supplier reported $4.55 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.14 by $1.41. The firm had revenue of $5.32 billion during the quarter, compared to the consensus estimate of $4.87 billion. Becton, Dickinson and had a return on equity of 13.30% and a net margin of 5.11%. The business’s revenue for the quarter was up 25.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.65 EPS. On average, equities analysts expect that Becton, Dickinson and Company will post 12.5 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 30th. Investors of record on Wednesday, June 9th will be issued a $0.83 dividend. The ex-dividend date is Tuesday, June 8th. This represents a $3.32 dividend on an annualized basis and a yield of 1.32%. Becton, Dickinson and’s dividend payout ratio is presently 32.55%.

A number of brokerages have issued reports on BDX. Citigroup upped their price target on shares of Becton, Dickinson and from $273.00 to $280.00 and gave the company a “neutral” rating in a research note on Friday, February 5th. Raymond James upped their price objective on shares of Becton, Dickinson and from $270.00 to $282.00 and gave the company an “outperform” rating in a report on Friday, January 29th. Zacks Investment Research downgraded shares of Becton, Dickinson and from a “buy” rating to a “hold” rating and set a $276.00 price objective on the stock. in a report on Wednesday, January 13th. TheStreet raised shares of Becton, Dickinson and from a “c+” rating to an “a-” rating in a report on Thursday, February 4th. Finally, Piper Sandler raised their price objective on shares of Becton, Dickinson and from $275.00 to $280.00 and gave the stock an “overweight” rating in a research report on Thursday, February 4th. Seven analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $281.08.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Read More: Monthly Dividend Stocks Can Provide Solid Income

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.